National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset
National Australian HCV Point-of-Care Testing Program: HCV 感染の診断と治療を強化するための指刺しポイントオブケア C 型肝炎検査の使用を評価するための観察コホート研究 - HCV 抗体検査の最小限のデータセット
The goal of this observational study is to learn if offering a point-of-care screening test for exposure to the Hepatitis C virus, before providing a diagnostic test for Hepatitis C infection can increase testing, diagnosis and treatment in Adults. Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of Hepatitis C viral infection. The main question it aims to answer is:
What proportion of the participants that have been diagnosed with HCV infection have started treatment when their records are reviewed 12 weeks after diagnosis?
Participants will have one in-person visit where they will provide informed consent and receive a finger-prick rapid result test for Hepatitis C infection. Participants with no previous Hepatitis C infection will have a screening test to see if they have an immune reaction to Hepatitis C. Participants who know they have been infected with Hepatitis C in the past, and all participants with a positive screening test result will then be given a Hepatitis C diagnostic test at this visit.
No treatment is provided as a part of this study, participants who are diagnosed with Hepatitis C infection will be referred to testing locations standard of care for any additional clinical assessments and treatment initiation. A review of the participant's records will be made 12 weeks after their Hepatitis C result and their treatment data are gathered.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Stephanie Davey, BSc
- 電話番号:+61293481404
- メール:sdavey@kirby.unsw.edu.au
研究連絡先のバックアップ
- 名前:David Silk, BSc
- 電話番号:+61293850900
- メール:dsilk@kirby.unsw.edu.au
研究場所
-
-
Australian Capital Territory
-
Canberra、Australian Capital Territory、オーストラリア
- まだ募集していません
- ACT Justice Health
-
コンタクト:
- Alex Misev
-
主任研究者:
- Alex Misev, Dr
-
-
New South Wales
-
Sydney、New South Wales、オーストラリア
- 募集
- Justice Health and Forensic Mental Health Network
-
コンタクト:
- Tracey Brown
-
-
Queensland
-
Bowen Hills、Queensland、オーストラリア、4006
- 積極的、募集していない
- Queensland Injectors Health Network Ltd
-
Brisbane、Queensland、オーストラリア
- 募集
- West Moreton Hospital and Health Service
-
コンタクト:
- Chris Wallis
- 電話番号:(07) 3810 1111
- メール:christopher.wallis@health.qld.gov.au
-
Cairns、Queensland、オーストラリア
- 募集
- Lotus Glen Correctional Centre
-
コンタクト:
- Kerry Williamson
- 電話番号:(07) 4093 3911
- メール:Kerry.Williamson@Corrections.qld.gov.au
-
Townsville、Queensland、オーストラリア、4810
- まだ募集していません
- Townsville Correctional Centre
-
コンタクト:
- John Morey
-
Woodford、Queensland、オーストラリア
- 募集
- Woodford Correctional Centre
-
コンタクト:
- Lyn Cadman
- 電話番号:(07) 5422 5200
- メール:lyn.cadman@health.qld.gov.au
-
-
South Australia
-
Adelaide、South Australia、オーストラリア
- まだ募集していません
- South Australian Prison Health Service
-
コンタクト:
- Tom Turnbull
-
主任研究者:
- Tom Turnbull
-
Hackney、South Australia、オーストラリア、5069
- まだ募集していません
- Hepatitis South Australia
-
コンタクト:
- Lisa Carter
-
-
Tasmania
-
Hobart、Tasmania、オーストラリア
- まだ募集していません
- Tasmanian Prison Service
-
コンタクト:
- Deborah Siddell
-
主任研究者:
- Meredith Stronach
-
-
Victoria
-
Melbourne、Victoria、オーストラリア
- 募集
- St Vincent's Hospital (Melbourne)
-
コンタクト:
- Alex Thompson
-
主任研究者:
- Alex Thompson, Prof
-
-
Western Australia
-
Beechina、Western Australia、オーストラリア、6558
- 募集
- Acacia Prison
-
コンタクト:
- Tahlia Kinnane
- 電話番号:(08) 9573 3300
- メール:tahlia.kinnane@serco-ap.com
-
Perth、Western Australia、オーストラリア、6000
- まだ募集していません
- WA Department of Justice
-
コンタクト:
- Holly Beasley
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Participants will be included from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated that approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.
説明
Inclusion Criteria:
- Provide informed consent
- ≥ 18 years of age.
Exclusion Criteria:
- Is unable or unwilling to provide informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
People at risk of HCV acquisition
Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing |
Participants will be offered finger-stick point-of-care testing for HCV |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing.
時間枠:12 weeks from enrolment
|
HCV treatment |
12 weeks from enrolment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate the proportion of people who accept point-of-care testing among those offered testing.
時間枠:Recruitment phase
|
Accepting testing |
Recruitment phase
|
|
To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested.
時間枠:Recruitment phase
|
Prevalence |
Recruitment phase
|
|
To evaluate the HCV antibody prevalence among people tested.
時間枠:Recruitment phase
|
Prevalence |
Recruitment phase
|
|
To evaluate the time to treatment uptake among people receiving point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment;
時間枠:52 weeks
|
Time to treatment |
52 weeks
|
|
To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.
時間枠:52 weeks
|
Initiation of treatment |
52 weeks
|
|
To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment following point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment;
時間枠:52 weeks
|
Completion of treatment |
52 weeks
|
|
To evaluate the proportion of participants who achieve an SVR following point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment
時間枠:52 weeks
|
SVR |
52 weeks
|
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.
時間枠:52 weeks
|
HCV negative |
52 weeks
|
|
To evaluate the cost of point-of-care HCV antibody testing prior to reflex HCV RNA testing compared to direct point-of-care HCV RNA testing and standard of care.
時間枠:52 weeks
|
Cost-effectiveness |
52 weeks
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- VHCRP2203
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。